PharmaGraphX

Log in Get Started

Ticagrelor

Brilinta

Uncategorized

Standard

Half-life

7 hours (active metabolite: 9 hours)

Protein Binding

99.7%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Maintenance aspirin doses > 100 mg reduce ticagrelor effectiveness
Do not start in patients planned for urgent CABG

Clinical alerts

Boxed warning

2 boxed warnings

Bleeding risk

Additive with other antithrombotics and NSAIDs

Mechanism of action

Reversibly binds P2Y12 ADP receptor on platelets, inhibiting platelet aggregation

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·ST-elevation Myocardial Infarction
·Myocardial Infarction (MI)
·Coronary Artery Disease
·Symptomatic Non-acute Intracranial Artery Occlusion
·Ischemic Stroke

Interactions

No curated interaction pairs are recorded for Ticagrelor. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Bleeding
Dyspnea
Headache
Dizziness

Food, alcohol & herbal

Alcohol · moderate

May increase bleeding risk

Pharmacokinetics

Half-life: 7 hours (active metabolite: 9 hours)
Protein binding: 99.7%
Metabolised by: CYP3A4
Inhibits: CYP3A4

Pregnancy & lactation

Not recorded for Ticagrelor. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Ticagrelor

Brilinta

Uncategorized

Standard

Half-life

7 hours (active metabolite: 9 hours)

Protein Binding

99.7%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Maintenance aspirin doses > 100 mg reduce ticagrelor effectiveness
Do not start in patients planned for urgent CABG

Clinical alerts

Boxed warning

2 boxed warnings

Bleeding risk

Additive with other antithrombotics and NSAIDs

Mechanism of action

Reversibly binds P2Y12 ADP receptor on platelets, inhibiting platelet aggregation

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·ST-elevation Myocardial Infarction
·Myocardial Infarction (MI)
·Coronary Artery Disease
·Symptomatic Non-acute Intracranial Artery Occlusion
·Ischemic Stroke

Interactions

No curated interaction pairs are recorded for Ticagrelor. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Bleeding
Dyspnea
Headache
Dizziness

Food, alcohol & herbal

Alcohol · moderate

May increase bleeding risk

Pharmacokinetics

Half-life: 7 hours (active metabolite: 9 hours)
Protein binding: 99.7%
Metabolised by: CYP3A4
Inhibits: CYP3A4

Pregnancy & lactation

Not recorded for Ticagrelor. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement